Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era
<h3>Aim</h3><p dir="ltr">In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii </i>and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p>...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513537126170624 |
|---|---|
| author | Emine Sehmen (22457614) |
| author2 | Esmeray Mutlu Yılmaz (22457617) Sevim Yetkin Pusa (22457620) Metin Özdemir (22457623) Yavuz Yiğit (17823383) |
| author2_role | author author author author |
| author_facet | Emine Sehmen (22457614) Esmeray Mutlu Yılmaz (22457617) Sevim Yetkin Pusa (22457620) Metin Özdemir (22457623) Yavuz Yiğit (17823383) |
| author_role | author |
| dc.creator.none.fl_str_mv | Emine Sehmen (22457614) Esmeray Mutlu Yılmaz (22457617) Sevim Yetkin Pusa (22457620) Metin Özdemir (22457623) Yavuz Yiğit (17823383) |
| dc.date.none.fl_str_mv | 2025-03-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1017/ash.2025.46 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Exploring_the_evolution_of_i_Acinetobacter_baumannii_i_and_i_Pseudomonas_aeruginosa_i_resistance_during_the_COVID-19_era/30393142 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Acinetobacter baumannii Pseudomonas aeruginosa Antibiotic resistance Antimicrobial susceptibility Intensive Care Unit (ICU) |
| dc.title.none.fl_str_mv | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Aim</h3><p dir="ltr">In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii </i>and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p><h3>Materials</h3><p dir="ltr">The study involved adult patients monitored in the ICUs of a secondary-level hospital from January 2019 to December 2022. Isolates of <i>A. baumannii </i>and <i>P. aeruginosa </i>were obtained from blood, urine, and respiratory samples. Identification and antibiotic susceptibility tests were conducted using the disk diffusion method and the VITEK 2 system.</p><h3>Results</h3><p dir="ltr">The average age of the patients was 61.3 ± 21.9 years (range: 18–95), with a majority of 1306 (51.6%) being male. During the pandemic, <i>A. baumannii</i> isolates showed a significant increase in resistance rates for several antibiotics compared to the pre-pandemic period: imipenem (96% vs 35.1%), amikacin (84.1% vs 14.4%), ciprofloxacin (96.9% vs 36.9%), trimethoprim-sulfamethoxazole (66.4% vs 27%), and ceftazidime (96.5% vs 33.3%) (all with <i>P</i>< .001). However, there was no significant change in colistin resistance rates in these isolates (0.9% vs 0%; <i>P</i>= .307). Similarly, <i>Pseudomonas aeruginosa</i> isolates exhibited significant increases in resistance rates during the pandemic compared to the pre-pandemic period: imipenem (51.5% vs 18.8%; <i>P</i>< .001), colistin (4.9% vs 0.6%; <i>P</i>= .009), amikacin (23.5% vs 4.4%; <i>P</i>< .001), ciprofloxacin (53.3% vs 13.8%; <i>P</i>< .001), and ceftazidime (39.2% vs 12.7%; <i>P</i>< .001).</p><h3>Conclusion</h3><p dir="ltr">Our results demonstrate a significant increase in antibiotic resistance levels in <i>Acinetobacter </i>and<i> Pseudomonas</i> strains associated with hospital-acquired infections or colonization during the COVID-19 pandemic.</p><h2>Other Information</h2><p dir="ltr">Published in: Antimicrobial Stewardship & Healthcare Epidemiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1017/ash.2025.46" target="_blank">https://dx.doi.org/10.1017/ash.2025.46</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_3010048dd49e34eae6e1c4fb2eee683f |
| identifier_str_mv | 10.1017/ash.2025.46 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30393142 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 eraEmine Sehmen (22457614)Esmeray Mutlu Yılmaz (22457617)Sevim Yetkin Pusa (22457620)Metin Özdemir (22457623)Yavuz Yiğit (17823383)Biomedical and clinical sciencesMedical microbiologyPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyAcinetobacter baumanniiPseudomonas aeruginosaAntibiotic resistanceAntimicrobial susceptibilityIntensive Care Unit (ICU)<h3>Aim</h3><p dir="ltr">In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii </i>and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p><h3>Materials</h3><p dir="ltr">The study involved adult patients monitored in the ICUs of a secondary-level hospital from January 2019 to December 2022. Isolates of <i>A. baumannii </i>and <i>P. aeruginosa </i>were obtained from blood, urine, and respiratory samples. Identification and antibiotic susceptibility tests were conducted using the disk diffusion method and the VITEK 2 system.</p><h3>Results</h3><p dir="ltr">The average age of the patients was 61.3 ± 21.9 years (range: 18–95), with a majority of 1306 (51.6%) being male. During the pandemic, <i>A. baumannii</i> isolates showed a significant increase in resistance rates for several antibiotics compared to the pre-pandemic period: imipenem (96% vs 35.1%), amikacin (84.1% vs 14.4%), ciprofloxacin (96.9% vs 36.9%), trimethoprim-sulfamethoxazole (66.4% vs 27%), and ceftazidime (96.5% vs 33.3%) (all with <i>P</i>< .001). However, there was no significant change in colistin resistance rates in these isolates (0.9% vs 0%; <i>P</i>= .307). Similarly, <i>Pseudomonas aeruginosa</i> isolates exhibited significant increases in resistance rates during the pandemic compared to the pre-pandemic period: imipenem (51.5% vs 18.8%; <i>P</i>< .001), colistin (4.9% vs 0.6%; <i>P</i>= .009), amikacin (23.5% vs 4.4%; <i>P</i>< .001), ciprofloxacin (53.3% vs 13.8%; <i>P</i>< .001), and ceftazidime (39.2% vs 12.7%; <i>P</i>< .001).</p><h3>Conclusion</h3><p dir="ltr">Our results demonstrate a significant increase in antibiotic resistance levels in <i>Acinetobacter </i>and<i> Pseudomonas</i> strains associated with hospital-acquired infections or colonization during the COVID-19 pandemic.</p><h2>Other Information</h2><p dir="ltr">Published in: Antimicrobial Stewardship & Healthcare Epidemiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1017/ash.2025.46" target="_blank">https://dx.doi.org/10.1017/ash.2025.46</a></p>2025-03-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1017/ash.2025.46https://figshare.com/articles/journal_contribution/Exploring_the_evolution_of_i_Acinetobacter_baumannii_i_and_i_Pseudomonas_aeruginosa_i_resistance_during_the_COVID-19_era/30393142CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/303931422025-03-01T00:00:00Z |
| spellingShingle | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era Emine Sehmen (22457614) Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Acinetobacter baumannii Pseudomonas aeruginosa Antibiotic resistance Antimicrobial susceptibility Intensive Care Unit (ICU) |
| status_str | publishedVersion |
| title | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| title_full | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| title_fullStr | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| title_full_unstemmed | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| title_short | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| title_sort | Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era |
| topic | Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Acinetobacter baumannii Pseudomonas aeruginosa Antibiotic resistance Antimicrobial susceptibility Intensive Care Unit (ICU) |